(Total Views: 441)
Posted On: 02/09/2021 9:19:10 AM
Post# of 153864
They will not be competing against us in the death-reduction arena, that is for sure.
203 total patients, 136 on drug (SYESAMI) and 67 on placebo.
91 survived in drug and 47 in placebo day 28.
The resultant p-value is 0.3193
They are checking day 60 saying that improved therapies affected the survival at day 28 (same case as us).
They will pursue EUA for critically ill patients and are evaluating recovery from respiratory failure, their primary end point.
We are now left alone in the death-reduction arena with results soon to be announced.
One more proof of how difficult is to treat COVID.
203 total patients, 136 on drug (SYESAMI) and 67 on placebo.
91 survived in drug and 47 in placebo day 28.
The resultant p-value is 0.3193
They are checking day 60 saying that improved therapies affected the survival at day 28 (same case as us).
They will pursue EUA for critically ill patients and are evaluating recovery from respiratory failure, their primary end point.
We are now left alone in the death-reduction arena with results soon to be announced.
One more proof of how difficult is to treat COVID.
(10)
(0)
